骨质疏松或骨质疏松性骨折的患病率及风险与非酒精性脂肪性肝病的关系:系统综述与Meta分析
该Meta分析纳入7项研究,检索PubMed、Web of Science、Embase、Scopus和Cochrane Library至2021年12月,评估非酒精性脂肪性肝病(NAFLD)与骨质疏松或骨质疏松性骨折患病率及风险的关系。结果显示NAFLD组骨质疏松或骨质疏松性骨折的患病率和风险均高于非NAFLD组,男性参数调整后风险仍较高,女性无显著差异。
要点
- NAFLD组骨质疏松或骨质疏松性骨折患病率高于非NAFLD组(OR=1.17,95%CI 1.04-1.31)。
- NAFLD组骨质疏松或骨质疏松性骨折风险高于非NAFLD组(OR=1.33,95%CI 1.24-1.44;OR=1.57,95%CI 1.08-2.29)。
- 参数调整后男性NAFLD组风险仍较高(OR=2.10,95%CI 1.36-3.25),女性无显著差异(OR=1.13,95%CI 0.86-1.48)。
核心结论
- 男性和女性中骨质疏松或骨质疏松性骨折的患病率和风险均与NAFLD显著相关。
- 作者指出NAFLD患者应定期监测骨密度和骨代谢指标以预防骨质疏松或骨质疏松性骨折。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Web of Science、Embase、Scopus和Cochrane Library五个数据库自建库至2021年12月。
- 纳入评估骨质疏松或骨质疏松性骨折与NAFLD关系的队列研究、横断面分析或病例对照研究,共纳入7项研究。
- 试验注册号:PROSPERO 2022 CRD42022304708。
主要发现
- NAFLD组骨质疏松或骨质疏松性骨折患病率高于非NAFLD组(OR=1.17,95%CI 1.04-1.31)。
- 男性和女性NAFLD组骨质疏松患病率均高于非NAFLD组(OR=1.46,95%CI 1.21-1.77;OR=1.48,95%CI 1.31-1.68)。
- NAFLD组骨质疏松或骨质疏松性骨折风险高于非NAFLD组(OR=1.33,95%CI 1.24-1.44;OR=1.57,95%CI 1.08-2.29)。
- 男性和女性NAFLD组骨质疏松或骨质疏松性骨折风险均高于非NAFLD组(OR=1.29,95%CI 1.14-1.47;OR=1.36,95%CI 1.25-1.48)。
- 参数调整后男性NAFLD组骨质疏松或骨质疏松性骨折风险高于非NAFLD组(OR=2.10,95%CI 1.36-3.25),女性无显著差异(OR=1.13,95%CI 0.86-1.48)。
关键数值与推荐
- NAFLD组骨质疏松或骨质疏松性骨折患病率较非NAFLD组升高,OR=1.17(95%CI 1.04-1.31)。
- 男性NAFLD组骨质疏松患病率较非NAFLD组升高,OR=1.46(95%CI 1.21-1.77);女性NAFLD组较非NAFLD组升高,OR=1.48(95%CI 1.31-1.68)。
- NAFLD组骨质疏松或骨质疏松性骨折风险较非NAFLD组升高,OR=1.33(95%CI 1.24-1.44);另一合并OR=1.57(95%CI 1.08-2.29)。
- 男性NAFLD组骨质疏松或骨质疏松性骨折风险较非NAFLD组升高,OR=1.29(95%CI 1.14-1.47);女性NAFLD组较非NAFLD组升高,OR=1.36(95%CI 1.25-1.48)。
- 参数调整后男性NAFLD组骨质疏松或骨质疏松性骨折风险较非NAFLD组升高,OR=2.10(95%CI 1.36-3.25);女性无显著差异,OR=1.13(95%CI 0.86-1.48)。
临床怎么用
- 作者指出NAFLD患者应定期监测骨密度和骨代谢指标以预防骨质疏松或骨质疏松性骨折。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: The aim of this study was to investigate the relationship between prevalence and risks of osteoporosis or osteoporotic fracture and NAFLD. Patients with NAFLD should be monitored regularly for bone mineral density and bone metabolism indicators to prevent osteoporosis or osteoporotic fractures. OBJECTIVES: The aim of this meta-analysis was to investigate the relationship between prevalence and risks of osteoporosis or osteoporotic fracture and non-alcoholic fatty liver disease (NAFLD). METHODS: Five databases, including PubMed, Web of Science, Embase, Scopus and Cochrane Library, were searched since the conception of these databases until December 2021. The cohort studies, cross-sectional analyses or case-control studies evaluating the relationship between osteoporosis or osteoporotic fracture and NAFLD were retrieved from these databases. Relevant data were extracted from the included studies, and a meta-analysis was performed. RESULTS: A total of seven studies were included. The prevalence of osteoporosis or osteoporotic fractures was higher in the NAFLD group than in the non-NAFLD group [OR = 1.17, 95%CI(1.04,1.31)], while the prevalence of osteoporosis was higher in the NAFLD group than in the non-NAFLD group [OR = 1.46, 95%CI (1.21,1.77) and OR = 1.48, 95%CI (1.31,1.68), respectively] in men and women. The risk of osteoporosis or osteoporotic fractures was higher in the NAFLD group than in the non-NAFLD group [OR = 1.33,95%CI (1.24,1.44) and OR = 1.57,95%CI (1.08,2.29), respectively]. The risk of osteoporosis or osteoporotic fractures was higher in male and female NAFLD groups than that in the non-NAFLD group [OR = 1.29, 95%CI(1.14,1.47) and OR = 1.36, 95%CI (1.25,1.48), respectively]. After parameter adjustment, the risk of osteoporosis or osteoporotic fracture was higher in the male NAFLD group than in the non-NAFLD group [OR = 2.10, 95%CI(1.36,3.25)], while no significant difference was found among women [OR = 1.13, 95%CI (0.86,1.48)]. CONCLUSIONS: The prevalence and risk of osteoporosis or osteoporotic fractures were significantly associated with NAFLD in men and women. TRIAL REGISTRATION: PROSPERO 2022 CRD42022304708.
引用
- Pan B, Cai J, Zhao P, et al. Relationship between prevalence and risk of osteoporosis or osteoporotic fracture with non-alcoholic fatty liver disease: A systematic review and meta-analysis. Osteoporos Int. 2022. PMID: 35764892. doi:10.1007/s00198-022-06459-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。